Category Archives: Stem Cell Doctors


Stem Cell Clinic > Stem Cell Doctors

CHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

By Stem Cell Doctors

Basel, 28 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Columvi® (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx) for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified who are ineligible for autologous stem cell transplant (ASCT). The standard second-line (2L) therapy for R/R DLBCL patients has historically been high-dose chemotherapy followed by stem cell transplant. New therapies have been recently introduced, however, not all patients can access or are eligible for these treatments.3 If approved, this Columvi combination could provide a much-needed, off-the-shelf treatment option. A final decision is expected from the European Commission in the near future.

Go here to read the rest:
CHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

By Stem Cell Doctors

Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strains Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strains

Originally posted here:
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

By Stem Cell Doctors

JENA, Germany, Feb. 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced acceptance of all submitted abstracts, featuring the role of vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS), to be presented during the 2025 American Academy of Dermatology (AAD) Annual Meeting, March 7 - 11, in Orlando, FL.

Read the rest here:
InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous…

By Stem Cell Doctors

Basel, February 28, 2025 – Novartis announced today it will present data from 17 abstracts, including investigator-initiated trials, across its immunology portfolio at the 2025 American Academy of Allergy Asthma and Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress and the 2025 American Academy of Dermatology (AAD) Annual Meeting.

Visit link:
Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous...

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

By Stem Cell Doctors

WESTLAKE VILLAGE, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will present two posters at the 2025 American Academy of Dermatology (AAD) annual meeting which will take place in Orlando, FL, from March 7 – 11, 2025.

Go here to see the original:
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting…

By Stem Cell Doctors

– Late-breaking oral presentation to highlight 52-week data of ESK-001 in a Phase 2 open-label extension (OLE) study in adults with moderate-to-severe plaque psoriasis –

Read more:
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting...

ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders’ Meeting

By Stem Cell Doctors

MADRID, Spain and CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A., a clinical-stage biopharmaceutical company focused on epigenetics for the development of therapies for diseases with significant unmet medical needs, today announced the results of voting at the Extraordinary General Shareholders' Meeting held today in Madrid. A total of 24,030,812 of the Company's issued and outstanding ordinary shares (representing 36.5312% of the share capital) were at the Meeting, either in person or represented by proxy.

Read the rest here:
ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting

→←